Clinical trial
A Phase I Study To Evaluate The Safety Of Cellular Immunotherapy Using Genetically Modified Autologous Cd20-Specific Cd8+ T Cell Clones For Patients With Relapsed Cd20+ Indolent Lymphomas
NCT00012207 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study To Evaluate The Safety Of Cellular Immunotherapy Using Genetically Modified Autologous Cd20-Specific Cd8+ T Cell Clones For Patients With Relapsed Cd20+ Indolent Lymphomas
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2000
- Completion date
- July 31, 2010
- Enrollment
- 12 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.